The trial will include a randomized control trial to evaluate the efficacy of using
Cannabidiol (CBD), a non-intoxicating cannabinoid, as an adjunctive to Prolonged Exposure
therapy (PE). The trial will compare PE + CBD to PE + placebo in a sample of 136 military
Veterans with PTSD at the VA San Diego Medical Center. The study represents the logical and
innovative next step for augmenting existing treatments and developing novel pharmacotherapy
for PTSD. Findings from the proposed RCT will inform clinical practice and policy by
investigating whether administration of CBD in the context of PE therapy will improve
treatment outcomes for military Veterans with PTSD.